Market Size of Europe Sodium-dependent Glucose Cotransporter 2 Industry
| Study Period | 2018 - 2029 |
| Base Year For Estimation | 2023 |
| Market Size (2024) | USD 1.30 Billion |
| Market Size (2029) | USD 2.02 Billion |
| CAGR (2024 - 2029) | 9.10 % |
| Market Concentration | High |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Europe Sodium-dependent Glucose Cotransporter 2 Market Analysis
The Europe Sodium-dependent Glucose Cotransporter 2 Market size is estimated at USD 1.30 billion in 2024, and is expected to reach USD 2.02 billion by 2029, growing at a CAGR of 9.10% during the forecast period (2024-2029).
The European region had witnessed an alarming increase in the prevalence of diabetes, in recent years. Diabetes is associated with many health complications. Patients with diabetes require many corrections throughout the day for maintaining nominal blood glucose levels, such as medications or ingestion of additional carbohydrates by monitoring their blood glucose levels.
The disease's growing incidence, prevalence, and progressive nature encouraged the development of new drugs to provide additional treatment options for diabetic patients. Non-insulin treatments, used as first-line therapies for patients with type 2 diabetes, currently capture more than half the sales in the anti-diabetic market. Over the past decade, two important classes entered this market: dipeptidyl peptidase-4 inhibitors (DPP-4) and sodium-glucose cotransporter-2 inhibitors (SGLT-2). These agents work in various ways to reduce blood sugar levels in people with type 2 diabetes. Some stimulate insulin secretion by the pancreas, and others improve the responsiveness of cells to insulin or prevent glucose production by the liver. Others slow the absorption of glucose after meals.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
Europe Sodium-dependent Glucose Cotransporter 2 Industry Segmentation
SGLT-2 inhibitors are an oral medication for treating type 2 diabetes in adults. They are prescription drugs called sodium-glucose co-transporter-2 inhibitors (SLGT2i) or gliflozins. The Europe Sodium-dependent Glucose Cotransporter 2 Market is segmented into drugs and geography . The report offers the value (in USD) and volume (in units) for the above segments.
| Drugs | |
| Invokana (Canagliflozin) | |
| Jardiance (Empagliflozin) | |
| Farxiga/Forxiga (Dapagliflozin) |
| Geography | |
| France | |
| Germany | |
| Italy | |
| Spain | |
| United Kingdom | |
| Russia | |
| Rest of Europe |
Europe Sodium-dependent Glucose Cotransporter 2 Market Size Summary
The European Sodium-Glucose Cotransporter Market is poised for significant growth, driven by the increasing prevalence of diabetes and the demand for effective management solutions. The region has seen a rise in diabetes cases, prompting the development of new pharmacological treatments, particularly non-insulin therapies like SGLT-2 inhibitors. These medications are crucial for managing blood glucose levels in type 2 diabetes patients, offering various mechanisms to enhance insulin sensitivity and reduce glucose absorption. The market's expansion is further supported by the growing healthcare expenditure on diabetes, which underscores the need for innovative and cost-effective treatment options. The collaborative efforts between government bodies and healthcare companies, such as the National Service Framework and the Association of British HealthTech Industries, are also contributing to improved diabetes care standards and market growth.
Germany stands out as a key player in the European SGLT-2 market, with a substantial share attributed to its high diabetes prevalence and advanced healthcare infrastructure. The country's regulatory environment, which includes stringent reimbursement and pricing policies, fosters market opportunities for pharmaceutical companies. The presence of major global manufacturers like Janssen, Eli Lilly, AstraZeneca, and Bristol Myers Squibb, along with strategic collaborations and product launches, further strengthens the market landscape. Recent approvals for SGLT-2 inhibitors, such as AstraZeneca's Forxiga and Eli Lilly's Jardiance, highlight the ongoing innovation and expansion of these drugs' indications, enhancing their role in diabetes and heart failure management across Europe.
Europe Sodium-dependent Glucose Cotransporter 2 Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.3 Market Restraints
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Bargaining Power of Suppliers
-
1.4.2 Bargaining Power of Consumers
-
1.4.3 Threat of New Entrants
-
1.4.4 Threat of Substitute Products and Services
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 Drugs
-
2.1.1 Invokana (Canagliflozin)
-
2.1.2 Jardiance (Empagliflozin)
-
2.1.3 Farxiga/Forxiga (Dapagliflozin)
-
-
2.2 Geography
-
2.2.1 France
-
2.2.2 Germany
-
2.2.3 Italy
-
2.2.4 Spain
-
2.2.5 United Kingdom
-
2.2.6 Russia
-
2.2.7 Rest of Europe
-
-
Europe Sodium-dependent Glucose Cotransporter 2 Market Size FAQs
How big is the Europe Sodium-dependent Glucose Cotransporter 2 Market?
The Europe Sodium-dependent Glucose Cotransporter 2 Market size is expected to reach USD 1.30 billion in 2024 and grow at a CAGR of 9.10% to reach USD 2.02 billion by 2029.
What is the current Europe Sodium-dependent Glucose Cotransporter 2 Market size?
In 2024, the Europe Sodium-dependent Glucose Cotransporter 2 Market size is expected to reach USD 1.30 billion.
